EQS-News: Vycor Medical Releases Financial Results for the Three and Nine Months Ended September 30, 2025

BOCA RATON, FL - November 14, 2025 (NEWMEDIAWIRE) - Vycor Medical, Inc. (“Vycor” or the “Company”) (OTCQB - VYCO), today announced financial results for the three and nine months ended September 30, 2025.

The Company operates through two business units: Vycor Medical, which produces the ViewSite™ Brain Access System (VBAS) for neurosurgery; and NovaVision®, a business in development which offers therapy programs to help patients recover from visual disorders after stroke or brain injury.

Company Highlights

The Vycor Medical division revenues for the three and nine months ended September 30, 2025 increased by 32% and 29%, respectively; most of the increase for the three months was in the US, with the majority of the nine-month growth being from international markets, a key strategic objective.

Operating profit for the three and nine months ended September 30, 2025 was $32,085 and $70,425, respectively, and non-GAAP operating profit for the three and nine months ended September 30, 2025 was $60,162 and $166,262, respectively, all substantial increases over the 2024 periods.

Three new clinical papers were published involving Vycor’s VBAS during the three months ended September 30, 2025 in addition to the six papers already published during the year, bringing the total published peer reviewed clinical papers to 50, with an additional 14 other clinical papers. One of the studies was a multi-center study on using VBAS for the evacuation of deep intracerebral hemorrhage, an important developing clinical area, in which the authors commented: “These findings suggest that our use of Vycor tubular retractors for minimally invasive ICH evacuation is promising”, and with a shorter length of stay for patients’ post-surgery than for existing methods. The second peer review paper reported on a novel pediatric surgical procedure for which VBAS was fundamentally important.

A new clinical study on NovaVision’s NeuroEyeCoach was published during 2025, comparing results from using the program at home or in a clinic. The study concluded that both home-based and clinic-based patients showed meaningful improvements with no significant differences between the two settings in activities of daily living improvements, validating NeuroEyeCoach as an effective tool, whether used clinically or accessed remotely. This is an important study for the company given the significant drive in healthcare systems worldwide to access digital technologies in home settings.

Financial Results

For the three months ended September 30, 2025, the Company reported revenue of $513,792, an increase of $122,940 (or 31%) over the same period in 2024. The Vycor Medical division (VBAS) generated revenue of $492,102, an increase of $119,265 (or 32%) over the same period in 2024, most of the increase being from growth in the US. The gross profit margin for 2025 was 88% versus 90% in 2024, with the lower gross margin in 2025 attributable to validation and shipping costs of new production runs. The NovaVision division, which remains in development, generated revenues of $21,690 for the three months ended September 30, 2025, versus $18,015 in 2024, and gross margin of 95%, compared to 92% for 2024.

For the nine months ended September 30, 2025, the Company reported revenue of $1,446,523, an increase of $312,425 (or 28%) over the same period in 2024. The Vycor Medical division (VBAS) generated revenue of $1,392,410, an increase of $313,766 (or 29%) over the same period in 2024, most of the increase being from growth in international markets. The gross profit margin for 2025 was 84% versus 90% in 2024, with the lower gross margin in 2025 attributable to validation and shipping costs of new production as well as higher international sales mix. The NovaVision division, which remains in development, generated revenues of $54,113 for the nine months ended September 30, 2025, versus $55,454 in 2024, and gross margin of 94%, compared to 93% for 2024.

For the three months ended September 30, 2025 the Company reported non-GAAP Cash Operating Expenses of $391,770 compared to $367,346 in 2024 and non-GAAP Operating Profit of $60,162 compared to a non-GAAP Operating Loss of $(13,290) in 2024.

For the nine months ended September 30, 2025 the Company reported non-GAAP Cash Operating Expenses of $1,059,475 compared to $998,112 in 2024 and non-GAAP Operating Profit of $166,262 compared to $27,021 in 2024.

Reconciliation of Non-GAAP Information

Non-GAAP Reconciliation

Management uses certain non-GAAP financial measures (including non-GAAP operating expenses and non-GAAP net loss and loss per share), which exclude non-cash depreciation of purchased assets and non-cash stock-based compensation. Management does not consider these costs in evaluating the continuing operations of the Company. Therefore, management calculates the non-GAAP financial measures provided in this earnings release excluding these costs and uses these non-GAAP financial measures to enable it to analyze further, and more consistently, the period-to-period financial performance of its core business operations. Management believes that providing investors with these non-GAAP measures gives them additional important information to enable them to assess, in the same way management assesses, the Company’s current and future continuing operations. There are limitations in using these non-GAAP financial measures because they are not prepared in accordance with GAAP and may be different from non-GAAP financial measures used by other companies. These non-GAAP financial measures should not be considered in isolation or as a substitute for GAAP financial measures. Investors and potential investors should consider non-GAAP financial measures only in conjunction with the Company’s consolidated financial statements prepared in accordance with GAAP. Set forth below are reconciliations of the non-GAAP financial measures to the comparable GAAP financial measures.

Three months ended September 30, 2025

On a GAAP basis the Company reported Operating Expenses of $419,847, an operating profit of $32,085, a net loss of $(157,249) and net loss of $(0.00) per share.

Vycor’s GAAP operating costs include non-cash depreciation of purchased assets ($15,868) and non-cash stock compensation charges ($12,209). The Company is providing additional non-GAAP financial measures that exclude these charges and expenses, and reconciliation of GAAP to non-GAAP results is provided in the tables included in this release.

On a non-GAAP basis, taking into account these adjustments, operating expenses were $391,770, non-GAAP operating profit was $60,160, and non-GAAP net loss was $(129,172) or $(0.00) per share.

Nine months ended September 30, 2025

On a GAAP basis the Company reported Operating Expenses of $1,155,312, an operating profit of $70,425, a net loss of $(334,110) and a loss of $(0.01) per share.

Vycor’s GAAP operating costs include non-cash depreciation of purchased assets ($46,999) and non-cash stock compensation charges ($48,838). The Company is providing additional non-GAAP financial measures that exclude these charges and expenses, and reconciliation of GAAP to non-GAAP results is provided in the tables included in this release.

On a non-GAAP basis, taking into account these adjustments, operating expenses were $1,059,475, non-GAAP operating profit was $166,262, and non-GAAP net loss was $(238,273) or $(0.01) per share.